• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

What Causes Facial Nerve Palsy?
Discussion Facial nerve palsy has been known for centuries, but in 1821 unilateral facial nerve paralysis was described by Sir Charles Bell. Bell’s palsy (BP) is a unilateral, acute facial paralysis that is clinically diagnosed after other etiologies have been excluded by appropriate history, physical examination and/or laboratory testing or imaging. Symptoms include abnormal movement of facial nerve. It can be associated with changes in facial sensation, hearing, taste or excessive tearing. The right and left sides are equally affected but bilateral BP is rare (0.3%). Paralysis can be complete or incomplete at prese...
Source: PediatricEducation.org - June 3, 2019 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Pre-treatment clinical assessment in head and neck cancer: United Kingdom National Multidisciplinary Guidelines.
Authors: Robson A, Sturman J, Williamson P, Conboy P, Penney S, Wood H Abstract This is the official guideline endorsed by the specialty associations involved in the care of head and neck cancer patients in the UK. This paper provides recommendations on the pre-treatment clinical assessment of patients presenting with head and neck cancer. Recommendations • Comorbidity data should be collected as it is important in the analysis of survival, quality of life and functional outcomes after treatment as well as for comparing results of different treatment regimens and different centres. (R) • Patients with hypertens...
Source: Journal of Laryngology and Otology - November 15, 2016 Category: ENT & OMF Tags: J Laryngol Otol Source Type: research

Lupus patients 'at higher risk of developing other health conditions'
People with lupus are at a greater risk of developing other health conditions than members of the general population.This is according to a new study conducted by the University of Nottingham and the Arthritis Research UK Primary Care Centre at Keele University, which examined the frequency of comorbidities associated with systemic lupus erythematosus in the UK between 1999 and 2012.A broad UK study Published in the medical journal Arthritis Care & Research, the study drew upon data from the UK Clinical Practice Research Datalink, identifying cases of lupus and matching each one by age, gender and practice to four heal...
Source: Arthritis Research UK - May 26, 2016 Category: Rheumatology Source Type: news

Burden of Comorbidity in Systemic Lupus Erythematosus in the UK, 1999–2012
ConclusionPeople with SLE in the UK have a greater burden of comorbidity and are more likely to develop CVD, stroke, ESRF, cancer, osteoporosis, and infection than people of the same age and sex.
Source: Arthritis Care and Research - May 25, 2016 Category: Rheumatology Authors: Frances Rees, Michael Doherty, Matthew Grainge, Peter Lanyon, Graham Davenport, Weiya Zhang Tags: Systemic Lupus Erythematosus Source Type: research

The burden of co‐morbidity in Systemic Lupus Erythematosus in the United Kingdom 1999‐2012
Conclusions: People with SLE in the UK have a greater burden of co‐morbidity and are more likely to develop CVD, stroke, ESRF, cancer, osteoporosis and infection than people of the same age and gender. This article is protected by copyright. All rights reserved.
Source: Arthritis Care and Research - October 16, 2015 Category: Rheumatology Authors: Frances Rees, Michael Doherty, Matthew Grainge, Peter Lanyon, Graham Davenport, Weiya Zhang Tags: Original Article Source Type: research